Epilepsy Associated with Systemic Autoimmune Disorders

Orrin Devinsky, MD, Adam Schein, BA, Souhel Najjar, MD
1Department of Neurology, NYU Langone School of Medicine, New York, NY
2Department of Neurology, NYU Langone School of Medicine, New York, NY
3Department of Neurology, NYU Langone School of Medicine, New York, NY
*Address correspondence to: Orrin Devinsky, MD, NYU Epilepsy Center, 223 East 34 Street, New York, NY 10016. E-mail: od4@nyu.edu

Systemic autoimmune disorders affect multiple organ systems. Brain involvement commonly causes seizures, which may be the presenting symptom. Systemic lupus erythematosus, Sjögren’s syndrome, Wegener’s granulomatosis, sarcoidosis, celiac disease, Crohn’s disease, Behcet’s, and Hashimoto’s encephalopathy are reviewed. Mechanisms underlying CNS pathology in systemic autoimmune disorders—and specifically factors predisposing these patients—are discussed, including vascular disease (e.g., prothrombotic state, anticardiolipin antibody, emboli, vasculitis), antineuronal antibodies, immune complexes, cytokines, metabolic disorders, infection, and therapy. Diagnostic and therapeutic strategies must be individualized for both the disorder and the patient. Systemic autoimmune disorders affect multiple organ systems and frequently involve the central and peripheral nervous systems. Seizures are among the most common neurological manifestation and occasionally can be the presenting symptom. There are many causes of seizures in systemic autoimmune disorders (Table 1), and the first clinical challenge is to determine not only the cause but also the significance of seizures. In some cases, they are clues to metabolic or infectious disorders or medication toxicity; in other cases, seizures herald a life-threatening progression of the underlying illness.

Table 1. Mechanisms of Seizures in Systemic Autoimmune Disorders

<table>
<thead>
<tr>
<th>Vascular disease</th>
<th>Platelet-fibrin thrombi (e.g., TTP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prothrombotic state</td>
<td>Anticardiolipin antibody</td>
</tr>
<tr>
<td>Emboli</td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td></td>
</tr>
<tr>
<td>Antineuronal antibodies</td>
<td></td>
</tr>
<tr>
<td>Immune complexes</td>
<td></td>
</tr>
<tr>
<td>Cytokines</td>
<td></td>
</tr>
<tr>
<td>Metabolic disorders</td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td></td>
</tr>
<tr>
<td>Therapy</td>
<td></td>
</tr>
<tr>
<td>Coincidence</td>
<td></td>
</tr>
</tbody>
</table>

antibodies are neuropathogenic in vitro, potentially causing seizures through direct neurotoxic effects (10). Other autoantibodies are also elevated in lupus patients with epilepsy (1, 11). To further complicate interpretation of antibody titers, some antiepileptic drugs can induce the lupus anticoagulant.

To examine the role of IgG class anticardiolipin antibodies in an epilepsy (non-SLE) population, the frequencies of these antibodies were determined in a cohort of 960 epilepsy patients and 580 reference subjects; 4.5% of the epilepsy patients had elevated titers, similar to a control group (11). However,
patients with chronic epilepsy and high seizure frequencies had elevated anticardiolipin titers relative to controls (11, 12). The question of cause and effect remains unanswered.

Among SLE patients, CSF antineuronal antibodies are increased in 90% with psychosis, encephalopathy, or seizures as compared to 11% without CNS disease and 25% of patients with stroke or movement disorder (13). CSF but not serum NMDA receptor subunit NR2 antibody levels correlate with neuropsychiatric symptoms, including seizures (14, 15). Antiribosomal P proteins elevated with CNS disease, including psychosis and seizures (1, 16). Notably, a lower risk of seizures correlates with higher anti-La Ab and the use of antimalarials (3, 17).

Neuropsychiatric features are common in pediatric SLE, with diverse manifestations and a high mortality (19). Seizures occur in 20% of pediatric lupus cases (20), with neuropsychiatric disorders in 35% (19). In a series of 185 pediatric SLE cases, 14 (7.5%) had neuropsychiatric features at presentation. Seizures were the most common neuropsychiatric manifestation, occurring in 84% of cases, stroke in 28%, psychosis in 22%. Seizures were generalized in 80% and recurrent in 63%. Compared to patients without neuropsychiatric features, affected patients had higher mean C3/C4 and anticardiolipin antibodies, and a lower percentage of elevated anti-dsDNA antibodies. In one large cohort of children with neuropsychiatric SLE, mortality decreased from 52% between 1985 and 1994 to 28% between 1995 and 2005.

The neuropathology of SLE sheds light on the pathogenesis of seizures and other neuropsychologic symptoms. In a consecutive series of 50 autopsies, there were no cases of active vasculitis and only two with evidence of healed vasculitis. However, more than a third were clinically—and incorrectly—diagnosed with CNS vasculitis (21). Mitral valvulitis was identified in 23 (46%), 9 with cerebral emboli. During the terminal illness, TTP was present in 14 (28%). Since four features of TTP—thrombocytopenic purpura, renal dysfunction, neurologic disorder, and fever—are common in SLE, only microangiopathic hemolytic anemia provided specific value in making the diagnosis. It is critical to review the blood smear in sick SLE patients.

**Sjögren’s Syndrome**

Sjögren’s syndrome (SS) is characterized by inflammation and destruction of lacrimal and salivary glands and may be associated with visceral involvement and vasculitis. Approximately 50% of SS patients have an isolated syndrome (primary SS) and another 50% of cases are often associated with other autoimmune disorder in a mixed connective tissue disorder (e.g., SLE, rheumatoid arthritis, scleroderma). Neurologic disorders occur in ~20% to 25%, with equal involvement of the peripheral and central nervous systems. Headache, polyneuropathy, cognitive dysfunction and mood disorder are common (22). Early nervous system involvement as primary presentation might precede the diagnosis of SS (23). Seizures, partial or generalized, occur in 3% of all SS patients (22), and ~8.5% of those with neurologic involvement (23). The clinical and neuroimaging findings in SS can mimic stroke and multiple sclerosis.

**Wegener’s Granulomatosis**

Wegener’s granulomatosis is a necrotizing, granulomatous vasculitis primarily involving the lungs and kidneys. The vasculitis affects medium and small arteries. The classical antineutrophil cytoplasmic antibody (c-ANCA) is often positive in necrotizing vasculitides, including Wegener’s. Peripheral and central neurologic involvement occurs in one third of patients (24). Peripheral nervous system disease is much more common than central involvement and is often a result of vasculitis, while CNS disease is often a result of granulomatous involvement. Many patients with CNS disease have granulomas in the ear, nose, or throat and have a refractory course. The reversible posterior leukoencephalopathy syndrome due to hypertension can complicate Wegener’s.

As a primary presenting manifestation of Wegener’s granulomatosis, seizures are rare (25), occurring in ~10% of patients with the neurological involvement (24). Seizures can be tonic-clonic, partial, or myoclonic.

**Sarcoidosis**

Sarcoidosis is a multiorgan noncaseating granulomatous disorder associated with oligoclonal CD4(+) T cell infiltrates and immune complexes. Neuropathological involvement is identified in 10% to 15% but is often asymptomatic (26). Neurological symptoms occur in ~5% (27), often within 2 years of presentation. Isolated neurologic manifestations are the primary presentation in approximately 50% of neurosarcoidosis (28). Blood and CSF ACE levels are variable in neurosarcoid and cannot be used to exclude the disorder (29). Two percent of all sarcoid cases have isolated nervous system disease involvement.

The differential diagnosis of neurosarcoidosis includes multiple sclerosis, Sjögren’s syndrome, acute disseminated encephalomyelitis, infection, tumor (e.g., lymphoma), and vasculitis. Cranial neuropathy, often reflecting basal leptomeningeal involvement, occurs in 80% and is a presenting feature in 50% of patients with neurosarcoidosis. Spread to the parenchyma may be via Virchow–Robin spaces (29). Brain T2-hyperintense lesions that enhance respond better to steroids than enhancing T2-hypointense and nonenhancing lesions (30). Tonic–clonic seizures are most common, but complex partial and myoclonic seizures are also described (27). Seizures occur more frequently in children (35%) than in adults (10%) with neurosarcoidosis (31–33). Seizures often mark severe, relapsing, and progressing disease (34). Seizures are more likely to respond when diagnosed early. However, if the granulomatous inflammation is not controlled, seizures may be refractory to AEDs (34). Although the inflammation is often controlled with corticosteroids, refractory cases often require other immunomodulatory therapies (e.g., anti-TNF-alpha antibodies). Epilepsy surgery can be effective in selected cases (36).
Epilepsy and Systemic Autoimmune Disorders

Table 2. Seizures, Epilepsy and Other Neurological Disorders Associated with Systemic Autoimmune Disorders

<table>
<thead>
<tr>
<th>Systemic Autoimmune Disorder</th>
<th>Frequency of Seizures</th>
<th>Common Seizure Types</th>
<th>Other Neurological and Neuropsychiatric Disorders</th>
<th>Frequency of Neurological Involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic Lupus Erythematosus (SLE)</td>
<td>7–40%</td>
<td>Generalized tonic–clonic (most common); complex partial; simple partial; myoclonic</td>
<td>Depression and psychosis; encephalopathy; cognitive dysfunction; headaches; stroke; posterior reversible encephalopathy syndrome; papilledema; pseudotumor cerebri; movement disorder (chorea); myelitis; peripheral neuropathy</td>
<td>30–50%</td>
</tr>
<tr>
<td>Sjögren's Syndrome (SS)</td>
<td>3% of all SS cases; 8.5% of cases with neurological involvement</td>
<td>Generalized tonic–clonic; complex partial</td>
<td>Headache; cognitive dysfunction; mood disorder; peripheral polyneuropathy</td>
<td>25%</td>
</tr>
<tr>
<td>Wegener's Granulomatosis</td>
<td>3% of all cases; 10% of cases with neurological involvement</td>
<td>Generalized tonic–clonic; complex partial; myoclonic</td>
<td>Peripheral neuropathy (mononeuropathy multiplex, distal symmetric polyneuropathy); cranial neuropathy; external ophthalmoparesis; strokes; cerebritis; posterior reversible encephalopathy syndrome</td>
<td>33%</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>10% (adult neurosarcoidosis) 35% (pediatric neurosarcoidosis)</td>
<td>Generalized tonic–clonic (most common); complex or simple partial myoclonic</td>
<td>Cranial neuropathy; leptomeningeal disease; headache; hydrocephalus; pituitary dysfunction; intraparenchymal lesions; white matter disease; myelopathy; polyneuropathy</td>
<td>5% (clinical studies); 10–15% (neuropathological studies)</td>
</tr>
<tr>
<td>Celiac Disease</td>
<td>1–5%?</td>
<td>Generalized tonic–clonic (most common); complex partial; absence</td>
<td>Ataxia; headache; cognitive dysfunction and dementia; mood disorder; vestibular dysfunction; cerebral calcification; peripheral neuropathy</td>
<td>10%?</td>
</tr>
<tr>
<td>Crohn's Disease</td>
<td>3.5–5.9%</td>
<td>Generalized tonic-clonic (most common); complex partial</td>
<td>Central demyelination; stroke; peripheral neuropathy; myelitis</td>
<td>19%–67%?</td>
</tr>
<tr>
<td>Behçet's Disease</td>
<td>2.2–5% (Middle Eastern and Asian); 27% (UK)</td>
<td>Generalized tonic–clonic (most common); complex partial; simple partial including epilepsia partialis continua</td>
<td>Par enchymatous lesions (meningoencephalitis and brainstem lesions); vascular (thrombosis of large veins and less often arteries, dural venous sinus thrombosis); intracranial hypertension</td>
<td>10% (within 10 years of the onset); 23% (in UK)</td>
</tr>
<tr>
<td>Hashimoto's Encephalopathy</td>
<td>66%</td>
<td>Generalized tonic–clonic; complex partial; simple partial including epilepsia partialis continua; absence status; myoclonic</td>
<td>Encephalopathy; delirium; depression; psychosis; stroke like; dementia; ataxia; chorea; myoclonus; tremor</td>
<td>100%</td>
</tr>
</tbody>
</table>
gluten protein in wheat and other grains (e.g., rye and barley) (36). The disorder has a large genetic component, as most patients have the HLA-DQ2 allele. The inflammatory response injures the villi and can lead to malabsorption and gastrointestinal symptoms. The diagnosis is often made serologically with IgA or IgG anti-gliadin antibodies or autoantibodies such as IgA anti-transglutaminase or anti-endomysial antibodies. In patients with IgA deficiency, IgG anti-endomysial antibodies are often positive. A small intestinal biopsy is the gold standard for diagnosis. The only treatment is a gluten-free diet. Celiac disease can cause neurological disorders in ~10% of cases (37), including ataxia, neuropathy (often carpal tunnel syndrome), vestibular dysfunction, seizures, migraines, and dementia. In cases with biopsy-proven celiac disease, neurological symptoms such as cerebellar ataxia are well documented (38). Compared to controls, children with celiac disease have only a slightly increased frequency of neurological symptoms (e.g., headache, mental retardation, neuropathy, and bipolar disorder), but ataxia is very rare (39). Vitamin E deficiency with improvement in neurological symptoms occurs in a minority of patients (40). Antigliadin antibodies cross-react with synapsin (1), providing a potential explanation for neurological symptoms (41). The prevalence of epilepsy in CD ranges from 1% to 5% (43). Seizures are often generalized tonic-clonic, but partial and occasionally absence seizures are also reported (42, 44). A recent epidemiologic study of nearly 29,000 subjects with CD and 143,000 controls found that CD increased by risk of epilepsy by 1.4-fold (47). The etiology of seizures in CD is not entirely known, but gluten neurotoxicity (48), or pyridoxine or folate deficiency (45) are suspected. In isolated patients with celiac disease and epilepsy refractory to AEDs, seizure control has been obtained with a gluten-free diet (48). In one study of 75 children with biopsy-proven celiac disease, 20% showed bilateral T2 white matter lesions, identified on MRI (49). There was no correlation between MRI findings and seizures (6/75; febrile 3, single TCS – 2; absence – 1) (49).

In rare and geographically limited regions (i.e., mainly Italy, Spain, Argentina), celiac disease is associated with occipital calcifications and epilepsy (50). Less than 200 cases of this disorder have been reported; occipital seizures are most common. In many cases, seizures are easily controlled; in others, the epilepsy is drug-resistant, and patients may progress to develop epileptic encephalopathy (50). The effectiveness of a gluten-free diet appears to decline with increasing duration of epilepsy and age. A gluten-free diet can halt the growth of the calcifications. CSF anti-gliadin antibodies may be present; most patients have the typical HLA phenotype. Celiac disease induced folic acid deficiency or environmental factors may interact with genetic susceptibility to cause calcifications (50).

Crohn’s Disease
Crohn’s disease is a T-cell mediated autoimmune disorder characterized by a chronic granulomatous inflammation of the intestines, although it can affect any portion of the gastrointestinal tract. Neurological and neuropsychiatric manifestations occur in 33% to 67% of Crohn’s patients (51, 52). Among Crohn’s disease patients, central demyelination occurs in 9% to 10% (53), epilepsy occurs in 3.5% to 5.9%, and stroke occurs in 4.7% to 7.1% but is usually unrelated to seizures (53, 54). Inflammatory, hypercoagulable, and genetic factors were suggested as potential mechanisms for seizures (55). In one epilepsy clinic, 4 out of 150 patients had Crohn’s disease (55). One-fifth of epilepsy patients had seizures during a flare of inflammatory bowel disease. One-third of patients had one seizure for which they did not receive AEDs but had a recurrent seizure during an exacerbation. Seizures are usually tonic-clonic but complex partial seizures also occur. MRI studies are usually normal.

Hashimoto’s Encephalopathy
Hashimoto’s encephalopathy (HE) is a rare, often underdiagnosed, lifethreatening condition characterized by relapsing and remitting encephalopathy, associated with antithyroid antibodies, particularly antithyroid peroxidase. HE is also referred to as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT). Brain and colleagues described the first case of HE in 1966 (72). The prevalence is estimated to be 2.1 out of 100,000 (73). HE affects both
children and adults; the mean age at onset is 44 years (74, 75). The clinical presentations are very heterogeneous and range from acute onset of impairment of consciousness, delirium, seizures, and stroke-like episodes to a more insidious presentation of chronic cognitive decline, dementia and other psychiatric disorders such as agitation, depression, and psychosis (74). Involuntary movements (choreaathetosis, myoclonus, and tremors) and ataxia can occur. Most patients are clinically euthyroid. More recently, new autoantibodies directed against the NH2-terminal of alpha-enolase (NAE) were discovered in 44% of HE patients (76). The most common presentation of patients with alpha-enolase (NAE) was acute encephalopathy (76).

Seizures affect 66% of HE patients (74, 75, 77). Seizures are either generalized tonic–clonic or complex partial, but simple partial, absence, and myoclonic seizures also occur. Convulsive and non-convulsive status epilepticus (SE) occur rarely in HE patients (78). We found only 7 HE patients with SE: 4 with convulsive SE, 2 with complex partial SE, and 1 each with absence SE and epilepsy partialis continua. Recurrent complex partial SE in a young woman with HE two weeks after missing scheduled intravenous immunoglobulin infusion, was also reported (79).

EEG abnormalities are present in 98% of HE patients (74). While EEG abnormalities may be non-specific (74, 80) (focal or diffuse slowing, FIRDA, triphasic waves, and epileptiform discharges), their severity often parallels the severity of encephalopathy. These EEG changes are often reversible with immunotherapy. CSF is reported to be abnormal in 80% cases (81), often with elevated protein (74, 81) and occasional oligoclonal bands and lymphocytic pleocytosis (81). Brain MRI is often normal but may show focal or diffuse atrophy, subcortical white matter changes (74), or edema (79).

The pathophysiology of HE and HE-associated seizures remains uncertain. A direct role of antithyroid antibodies has not been clearly established. These antibodies are often viewed as a biomarker of underlying autoimmunity rather than being pathogenic, despite the detection of the theses antibodies in the CSF (82). Other postulated mechanisms include circulating immune complexes (82) or neuronal autoantibodies, such as anti-glutamic acid decarboxylase antibodies and autoantibodies targeting a 36kD antigen derived from the cerebral cortex (83). Autoimmune vasculitis was also proposed as a possible etiology of HE, based on the presence of alpha-enolase antibodies that occur with other vasculitic syndromes such as Kawasaki disease (84, 85), the SPECT findings of cerebral hypoperfusion (74) in HE cases, and the limited neuropathological reports for HE (85).

Glucocorticosteroids are the mainstay treatment for HE, and the response is frequently prompt. The dose and duration of steroid treatment are titrated to the clinical response and the risk of relapse rather than to the antithyroid antibodies titers. For steroid-resistant or dependent cases, intravenous immunoglobulins, immunosuppressant drugs, or plasma exchange might be effective. During the relapsing phase of HE, the role of antiepileptic medications alone in controlling seizures is often limited, unless inflammation is controlled. Antithyroid antibodies should be obtained in patients with subacute encephalopathy and unexplained seizures or atypical neuropsychiatric manifestation.

Conclusions
Seizures often complicate systemic autoimmune disorders through a variety of mechanisms. These include primary immunological effects on brain tissue (e.g., antineuronal antibodies, immune complexes, cytokines), effects of vascular disease (e.g., prothrombotic state, anticardiolipin antibody, emboli, vasculitis), metabolic disorders, infection, and complications of therapy. Understanding the pathophysiology of epileptogenesis in these patients may help provide therapeutic targets for specific patients and more broadly, for epilepsy patients without systemic autoimmune disorders. Further, the expanding group of autoimmune encephalitides (e.g., auto-antibodies to the NMDA, GABA-B and AMPA receptors and to LGI1, CASPR2 and Contactin-2, components of the voltage-gated potassium channel complex) may be relevant to some of the epilepsies complicating systemic autoimmune disorders. Supporting this notion, animal models using anti-NMDA receptor antibodies can induce neuropsychiatric changes that mimic cognitive and behavioral disorders in SLE.

References


49. McGowan KE, Castiglione DA, Yang B, Selmanowitz V, Silverman EE, Silverman EE. Epilepsy and Systemic Autoimmune Disorders
American Epilepsy Society

Epilepsy Currents Journal
Disclosure of Potential Conflicts of Interest

Section #1  Identifying Information

1. Today's Date: 12/13

2. First Name  Last Name  Degree

3. Are you the Main Assigned Author?  Yes  No
   If no, enter your name as co-author:

4. Manuscript/Article Title:

5. Journal Issue you are submitting for:

Section #2  The Work Under Consideration for Publication
Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board